ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the full-year financial outlook has been upgraded to reflect the current performance and outlook for the remainder of the year. Revenue is ...

Earnings Call Insights: ALK-Abelló A/S (OTCPK:AKBLF) Q4 2024 Revenue for 2025 is projected to grow by 9% to 13%, supported by double-digit growth in tablet sales across all regions. North America ...

ALK B’s level of debt is appropriate relative to its total equity, at 22%. ALK B is not taking on too much debt commitment, which may be constraining for future growth.

Alk-Abello A-S (B) will report earnings from the most recent quarter on May 9. Analysts on Wall Street predict Alk-Abello A-S (B) will release earnings per share of DKK 3.49. Watch Alk-Abello A-S ...

Shareholders of ALK-Abelló A/S (CPH:ALK B) will be pleased this week, given that the stock price is up 11% to ø1,925 following its latest first-quarter results. It was an okay result overall ...

SAN FRANCISCO (MarketWatch) -- Schering AG said Tuesday it will sell its 50% interest in the German distributor ALK-Scherax Arzneimittel GmbH to Danish pharmaceutical company ALK-Abello A/S, which ...

ALK-Abello, which is among the world' s leading providers of vaccines against allergies, reported net profit of DKK44 million on sales of DKK1.49 billion in the financial year ending Aug. 31 .

Shareholders of ALK-Abelló A/S (CPH:ALK B) will be pleased this week, given that the stock price is up 11% to ø1,925 following its latest first-quarter results. It was an okay result overall, with ...